Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Community-acquired pneumonia (CAP) is a significant cause of hospitalization and mortality.
• Antibiotic resistance poses a challenge in CAP treatment, necessitating evaluation of effective therapeutic options.
• Ampicillin/sulbactam and cefamandole are commonly used antibiotics for bacterial infections.

Purpose of the Study:

• To compare the clinical efficacy of ampicillin/sulbactam versus cefamandole in hospitalized patients with community-acquired pneumonia.
• To assess treatment success rates and identify potential differences in outcomes between the two antibiotic regimens.

Main Methods:

• A randomized prospective study involving 75 hospitalized patients with CAP.
• Patients were treated with either ampicillin/sulbactam (n=37) or cefamandole (n=38).
• Demographic, clinical characteristics, severity of illness, and isolated pathogens were analyzed.

Main Results:

• Both ampicillin/sulbactam and cefamandole demonstrated effectiveness in treating CAP.
• Ampicillin/sulbactam achieved an overall successful treatment rate of 97%, compared to 81% for cefamandole (p=0.05).
• Patient groups were similar in age, clinical characteristics, and severity of illness, indicating comparable baseline conditions.

Conclusions:

• Ampicillin/sulbactam demonstrated superior overall clinical efficacy compared to cefamandole for community-acquired pneumonia.
• Both antibiotics are effective, but ampicillin/sulbactam offers a statistically significant advantage in treatment success.
• Further research may explore specific pathogen susceptibilities and long-term outcomes.